Literature DB >> 2830814

Combinations of rifampin or rifabutine plus ethambutol against Mycobacterium avium complex. Bactericidal synergistic, and bacteriostatic additive or synergistic effects.

L B Heifets1, M D Iseman, P J Lindholm-Levy.   

Abstract

Ethambutol, when combined with rifampin or rifabutine (ansamycin, LM427), produced an additive inhibitory effect against most of the tested M avium complex strains (12 of 16 with rifampin, 13 of 16 with rifabutine). The inhibitory effect was synergistic for the remaining 4 of 16 and 3 of 16 strains. This relationship reduced the minimal inhibitory concentrations for each drug in combination. In addition, the minimal bactericidal concentrations of all 3 drugs were reduced because of synergistic bactericidal activity in 6 of 6 strains tested.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2830814     DOI: 10.1164/ajrccm/137.3.711

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  17 in total

Review 1.  Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.

Authors:  E Nuermberger; J Grosset
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-13       Impact factor: 3.267

2.  In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins.

Authors:  H Saito; H Tomioka; K Sato; M Emori; T Yamane; K Yamashita; K Hosoe; T Hidaka
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 3.  Bacterial challenges and evolving antibacterial drug strategy.

Authors:  B Watt; J G Collee
Journal:  Postgrad Med J       Date:  1992-01       Impact factor: 2.401

Review 4.  Future directions in the development of new antitubercular drugs. Where do we go from here?

Authors:  W W Yew; C H Chau
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

5.  In vivo activities of newer rifamycin analogs against Mycobacterium avium infection.

Authors:  S P Klemens; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

6.  Susceptibility of mycobacteria to fusidic acid.

Authors:  S E Hoffner; B Olsson-Liljequist; K J Rydgård; S B Svenson; G Källenius
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-04       Impact factor: 3.267

7.  A bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions.

Authors:  P S Skinner; S K Furney; M R Jacobs; G Klopman; J J Ellner; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

8.  Therapeutic efficacy of the benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits.

Authors:  M Emori; H Saito; K Sato; H Tomioka; T Setogawa; T Hidaka
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

9.  Effects of antimicrobial agents on survival of Mycobacterium avium complex inside alveolar macrophages obtained from patients with human immunodeficiency virus infection.

Authors:  D M Yajko; P S Nassos; C A Sanders; W K Hadley
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

10.  In vitro activities of rifabutin, azithromycin, ciprofloxacin, clarithromycin, clofazimine, ethambutol, and amikacin in combinations of two, three, and four drugs against Mycobacterium avium.

Authors:  D M Yajko; C A Sanders; J J Madej; V L Cawthon; W K Hadley
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.